Payment overview · 2025
General Payments
$566.59
29 reported records · 8 companies
Healthcare provider profile · identity verified
Karen Paczkowski, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SCRANTON, PA · NPI 1326000290
Verified facts
What the public records show
CMS Open Payments records show Karen Paczkowski, MD received $566.59 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.40 | 32.4% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.17 | 25.8% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $68.08 | 12.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.42 | 11.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.91 | 6.3% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $29.54 | 5.2% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $24.40 | 4.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.67 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.59 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $183.40 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.90 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.90 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.27 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $68.08 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.18 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 212 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 703 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 483 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 392 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 99 |
| Furosemide | Furosemide | 325 | 84 |
| Alprazolam | Alprazolam | 318 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 91 |
| Gabapentin | Gabapentin | 240 | 79 |
| Metformin Hcl | Metformin Hcl | 238 | 64 |
| Eliquis | Apixaban | 220 | 44 |
| Valsartan | Valsartan | 217 | 69 |
| Lisinopril | Lisinopril | 214 | 60 |
| Jardiance | Empagliflozin | 212 | 45 |
| Omeprazole | Omeprazole | 204 | 60 |
| Spironolactone | Spironolactone | 200 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 40 |
| Prednisone | Prednisone | 177 | 77 |
| Potassium Chloride | Potassium Chloride | 174 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 38 |
| Methylprednisolone | Methylprednisolone | 144 | 117 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 40 |
| Losartan Potassium | Losartan Potassium | 138 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 40 |
| Simvastatin | Simvastatin | 122 | 35 |
| Lorazepam | Lorazepam | 121 | 35 |
| Famotidine | Famotidine | 112 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 107 | 32 |
| Chlorthalidone | Chlorthalidone | 106 | 27 |
| Montelukast Sodium | Montelukast Sodium | 103 | 23 |
| Tramadol Hcl | Tramadol Hcl | 102 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 33 |
| Clonazepam | Clonazepam | 98 | 23 |
| Allopurinol | Allopurinol | 95 | 29 |
| Pregabalin | Pregabalin | 95 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 77 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 39 |
| Trazodone Hcl | Trazodone Hcl | 86 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 31 |
| Synthroid | Levothyroxine Sodium | 78 | 26 |
| Cefuroxime | Cefuroxime Axetil | 72 | 59 |
| Irbesartan | Irbesartan | 71 | 19 |
| Ozempic | Semaglutide | 71 | 25 |
| Donepezil Hcl | Donepezil Hcl | 70 | 17 |
| Xarelto | Rivaroxaban | 70 | 14 |
| Sertraline Hcl | Sertraline Hcl | 68 | 20 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 65 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 32 |
| Atenolol | Atenolol | 60 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Meloxicam | Meloxicam | 56 | 12 |
| Benazepril Hcl | Benazepril Hcl | 55 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 43 |
| Azithromycin | Azithromycin | 50 | 40 |
| Klor-Con M20 | Potassium Chloride | 49 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 34 |
| Enalapril Maleate | Enalapril Maleate | 47 | 12 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 18 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Nystatin | Nystatin | 45 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Carvedilol | Carvedilol | 43 | suppressed |
| Glimepiride | Glimepiride | 43 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 15 |
| Metformin Hcl Er | Metformin Hcl | 40 | 11 |
| Felodipine Er | Felodipine | 36 | 11 |
| Finasteride | Finasteride | 36 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 26 |
| Baclofen | Baclofen | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 18 |
| Diazepam | Diazepam | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 27 |
| Meclizine Hcl | Meclizine Hcl | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 22 |
| Colchicine | Colchicine | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Torsemide | Torsemide | 28 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 13 |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Cefdinir | Cefdinir | 21 | 17 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 18 |
| Indapamide | Indapamide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | 12 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Mesalamine | Mesalamine | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Topiramate | Topiramate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.59 · 29 records | ABBVIE INC. | CAMZYOS, FUROSCIX, JARDIANCE, Leqembi, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error